SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,374,201 | +47.9% | 65,657 | +49.3% | 0.04% | +38.5% |
| Q1 2023 | $928,836 | +246.2% | 43,979 | +317.1% | 0.03% | +225.0% |
| Q4 2022 | $268,319 | -19.7% | 10,543 | -29.7% | 0.01% | -77.1% |
| Q4 2020 | $334,000 | -20.1% | 14,997 | -47.0% | 0.04% | +29.6% |
| Q3 2020 | $418,000 | +62.0% | 28,309 | +62.4% | 0.03% | +50.0% |
| Q2 2020 | $258,000 | -26.9% | 17,435 | -56.7% | 0.02% | -53.8% |
| Q4 2017 | $353,000 | +165.4% | 40,274 | +254.8% | 0.04% | +14.7% |
| Q3 2017 | $133,000 | -53.0% | 11,351 | -44.9% | 0.03% | -5.6% |
| Q1 2017 | $283,000 | – | 20,595 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |